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Introduction
Th   e National Cancer Institute deﬁ  nes personalized medi-
cine as ‘a form of medicine that uses information about a 
person’s genes, proteins, and environment to prevent, 
diagnose, and treat disease’ [1]. Personalized cancer 
medicine has existed in breast cancer since the late 1980s 
when beneﬁ  ts of tamoxifen were found to be limited to 
patients with tumors expressing estrogen receptors (ERs) 
[2]. Th   is personalized treatment has advanced further in 
recent times through the discovery of erbB2/HER2 gene 
ampliﬁ   cation and its subsequent targeted treatments 
such as trastuzumab and lapatinib [3,4].
Until very recently, personalized cancer medicine in 
breast cancer relied on only two predictive markers, ER 
and  erbB2/HER2. Th   e advent of gene expression 
proﬁ  ling, however, has led to a paradigm shift in breast 
cancer medicine. Breast cancer is now recognized not as 
a single disease with variable morphology, but as at least 
four molecularly distinct neoplastic disorders: basal-like 
breast cancer, HER2-positive breast cancer, luminal-A 
breast cancer, and luminal-B breast cancer [5-8]. Although 
the immediate additional clinical value of this molecular 
classiﬁ   cation is limited by its close correlation to 
traditional methods of testing for ER and HER2, the 
identiﬁ   cation of genetic aberrations that underlie 
molecularly distinct subclasses of breast cancer has 
revealed new therapeutic targets and has reshaped breast 
cancer clinical trial design.
Th   e subtypes most in need of therapeutic advances are 
basal-like breast cancer and luminal-B breast cancer, 
where therapeutic resistance is common and where 
advances in molecular proﬁ  ling have identiﬁ  ed promising 
new therapeutic targets. In the present review article, we 
discuss the deﬁ   nition of luminal-B breast cancer, the 
clinical behavior and pathological features of luminal-B 
breast cancer, and emerging molecular targets for 
improved therapy (see Table 1 for a summary).
Defi  ning luminal-B breast cancer
Microarray technology has enabled better understanding 
of cancer biology at a molecular level through the 
interrogation of tens of thousands of expressed genes 
simultaneously. In breast cancer, hierarchical clustering 
of a series of breast cancers based upon a set of diﬀ  erently 
expressed intrinsic genes between individual patients led 
to the identiﬁ  cation of a novel molecular classiﬁ  cation of 
breast cancer [7]. Th   e so-called intrinsic molecular classi-
ﬁ     cation of human breast cancer includes basal-like, 
HER2-positive, luminal-A and luminal-B subtypes. Th  ese 
subtypes have been associated with distinct pathological 
features and clinical outcome: basal-like breast cancer is 
predominantly triple-negative, with absent expression of 
ER, progesterone receptor (PR) and normal erbB2/HER2
gene copy number; HER2-positive breast cancer is erbB2/
HER2 gene ampliﬁ   ed and is associated with poorer 
outcomes when untreated; and both luminal-A and 
luminal-B breast cancers are ER-positive, although 
luminal-B cancers have poorer outcomes [9].
Th  e seminal work of Perou and colleagues initially 
identiﬁ   ed molecular portraits of breast cancer based 
upon gene expression proﬁ   ling of 65 breast cancer 
samples from 42 individual patients using cDNA 
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© 2011 BioMed Central Ltdmicroarrays [7]. Th  eir  classiﬁ  cation was based upon the 
premise that individual diﬀ   erences in gene expression 
should be greater than diﬀ   erences in gene expression 
from paired tumor samples derived from the same 
patient. Th  ey  identiﬁ   ed a set of 496 genes that 
demonstrated signiﬁ     cantly greater variation between 
individual tumors than within paired tumor samples 
from the same individual. When this intrinsic gene set 
was used to perform hierarchical clustering of their 
tumor samples, four subgroups were identiﬁ  ed:  basal-
like, based upon similari  ties in gene expression to basal 
epithelial cells in the normal breast; Erb-B2 positive, 
based upon increased expression of genes in the erbB2/
HER2 gene amplicon on chromosome 17q12; luminal, 
based upon similarities in gene expression to luminal 
epithelial cells in the normal breast; and normal breast-
like, based upon the inclusion of three normal, 
nonmalignant breast samples. In this initial study, no 
distinction between luminal-A and luminal-B breast 
cancers was identiﬁ  ed.
A subsequent study from the same group extended the 
sample size to 78 breast cancers (including 40 from the 
original publication) using hierarchical clustering with an 
intrinsic gene set of 456 cDNA clones. Extension of the 
sample size allowed for the identiﬁ   cation of subsets 
within the luminal cluster (47 tumors): luminal A (32 
tumors), luminal B (ﬁ   ve tumors), and luminal C (10 
tumors) [8]. Luminal B and luminal C demonstrated 
lower expression of ER-related genes compared with 
luminal-A tumors, while luminal C was further 
distinguished from luminal A and luminal B by high 
expression of a set of genes shared with basal-like and 
HER2-positive subtypes, but of unknown function [8]. 
Compared with luminal-A tumors, poorer outcomes 
were observed in luminal-B and luminal-C tumors. It is 
well recognized that hierarchical clustering based on a 
small sample number can result in unstable molecular 
classiﬁ   cations. Later studies failed to reproduce the 
luminal-C subtype and the luminal classiﬁ  cation  was 
collapsed into two subtypes: luminal-A with high 
expression of ER-regulated genes and favorable long-
term outcome, and luminal-B with lower expression of 
ER-regulated genes and poorer long-term outcome.
Multiple gene expression studies have reproduced 
luminal-A and luminal-B subtypes. Both subtypes have 
expression patterns reminiscent of the luminal epithelial 
component of the breast, including expression of luminal 
cytokeratins 8/18, ER and genes associated with ER 
activation such as CCND1 (cyclin D1). Th  e major 
molecular distinction between the two luminal subtypes 
is that, in general, luminal B has lower expression of ER-
related genes and higher expression of proliferative genes 
[6,8,10]. Luminal-B tumors also demonstrate increased 
expression of growth receptor signaling genes, although 
only 10% of tumors were HER2-positive by immuno-
histochemistry [11]. A review of several gene expression 
studies noted that approximately 20% of luminal-B breast 
cancers were HER2-positive by immunohistochemistry 
[5]. Since HER2-positive breast cancers are treated very 
diﬀ   erently from HER2-negative breast cancers, a 
clinically meaningful classiﬁ  er of luminal-B breast cancer 
should not include HER2-positive breast cancers [9]. 
Approximately 30% of HER2-positive tumors deﬁ  ned by 
immunohistochemistry are assigned to the luminal-B 
subtype. Most of the tumors are also ER-positive by 
immunohistochemistry or ESR1 gene expression [6,9]. 
Th  e clinical relevance of whether an ER-positive breast 
cancer with overexpression of HER2 is classiﬁ  ed  as 
HER2-positive or as luminal B by the intrinsic molecular 
classiﬁ  cation remains to be determined.
In many subsequent studies, luminal-B breast cancer 
has been deﬁ   ned as ER-positive breast cancer with 
increased proliferation [5]. In gene expression studies, 
proliferation genes such as CCNB1, MKI67 and MYBL2 
are more highly expressed in luminal-B compared with 
luminal-A subtypes [12], correlating with a higher 
proportion of histological grade III also observed in 
luminal-B cancers [9].
Since the seminal paper of Perou and colleagues ﬁ  rst 
identiﬁ   ed the intrinsic molecular subtypes of breast 
cancer, there have been various single subtype predictors 
(SSPs) that have been developed to identify the molecular 
subtype of an individual breast cancer [6,13,14]. Th  ese 
SSPs diﬀ  er in the intrinsic gene list that is used to deﬁ  ne 
molecular classiﬁ  cation. Recently, the reproducibility of 
subtype assignment across these three SSPs was 
Table 1. Luminal-B breast cancer
Genes overexpressed in gene expression profi  ling
  ER and ER-regulated genes
 Proliferation-related  genes
  Cell cycle genes
Histopathological features 
 ER-positive
 High  grade
 High  Ki-67
Clinical features 
  Poorer disease-free survival
  Increased risk of early relapse
  Predisposition to relapse in bone and pleura
  Relative insensitivity to endocrine therapy compared with luminal-A 
 subtype
  Relative insensitivity to chemotherapy compared with basal-like and 
 HER2-positive  subtypes
ER, estrogen receptor.
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publicly available datasets involving nearly 800 patients 
and performing two-way average-linkage hierarchical 
cluster analysis using ﬁ   ve distinct intrinsic gene lists. 
Whilst the basal-like and HER2 subtypes could be 
reproducibly identiﬁ  ed by independent observers, none 
of the classiﬁ  cation systems could produce substantial 
agreement in subdividing luminal cancers [15]. A similar 
study by Weigelt and colleagues produced similar con-
clusions [16]. Although this lack of agreement is trouble-
some, it is perhaps not surprising as the initial molecular 
classiﬁ  cation was based upon only 42 individuals with 
breast cancer [7].
Proliferation has been consistently identiﬁ   ed as the 
most important feature of several prognostic multigene 
signatures, including the intrinsic molecular classiﬁ  cation 
[5,17]. In ER-positive/HER2-negative tumors, prolifera  tion 
is the strongest predictor of early relapse risk that 
diﬀ  eren  tiates high-risk luminal-B tumors from low-risk 
luminal-A tumors [5,18]. Whilst ER is bimodally 
expressed (meaning the overwhelming majority of cases 
are either completely ER-positive or unambiguously ER-
negative) in breast cancer, thus allowing a meaningful 
cut-oﬀ    point to be applied [19], proliferation-related 
genes are expressed along a unimodal continuum. Th  is 
makes it extremely diﬃ   cult to apply any meaningful cut-
oﬀ    point that diﬀ   erentiates between high and low 
proliferative tumors in a reproducible manner. Th  is is 
evident in the diﬀ  erences in subtype assignment between 
luminal-B and luminal-A tumors across SSPs, where 
tumors with a level of proliferation around the median 
value may be inconsis  tently classiﬁ  ed by SSPs that use 
diﬀ  erent proliferation-driven intrinsic gene lists.
Clinical features of luminal-B breast cancer
Since the earliest studies of the intrinsic molecular 
subtypes in breast cancer, the deﬁ  ning feature of luminal-
B breast cancer has been its poor outcome compared 
with the luminal-A subtype [7]. Overall survival in 
untreated luminal-B breast cancer is similar to the basal-
like and HER2-positive subgroups, which are widely 
recognized as high risk. One study used a 50-gene 
classiﬁ  er to assign intrinsic subtypes to 761 untreated 
breast cancer patients, and correlated subtype with 
outcome. In a multivariate analysis of untreated early 
breast cancer, using the luminal-A subtype as a reference, 
luminal-B breast cancers were demonstrated to have a 
hazard ratio of 2.43 (P <0.0001) for relapse-free survival 
(RFS), similar to hazard ratios for erbB2/HER2 ampliﬁ  ed 
(2.53, P = 0.00012) tumors [13].
Th   e increased relapse risk associated with the luminal-
B phenotype appears to be limited to the early period 
after surgery. Since increased proliferation is the hallmark 
of luminal-B cancer [20], it is not surprising that 
increased relapse rates observed in luminal-B tumors are 
limited to the ﬁ   rst 5 years after diagnosis, with no 
diﬀ  erence in distant relapse beyond 5 years [21]. In a 
series of 831 untreated node-negative breast cancers, 
curated from ﬁ   ve publicly available gene expression 
datasets, we found the hazard ratio for distant metastases 
of luminal-B subtype compared with luminal-A subtype 
to be 2.86 (P <0.01) for early metastases (<5 years) and 
0.65 (P = nonsigniﬁ  cant) for late metastases (≥5 years) 
(Table 2).
Th  ere are diﬀ  erences in the anatomic sites of relapse 
according to molecular subtypes. Th  e increased inci-
dence of brain metastases in HER2-positive and basal-
like breast cancer is well recognized [22,23]. Luminal 
breast cancers appear to have a predilection for meta-
stasis to bone and pleura. In a small study of 81 patients 
with metastatic breast cancer, no diﬀ  erences in sites of 
metastasis were observed between luminal-B and 
luminal-A breast cancers [24].
Several studies have suggested luminal-B breast cancer 
is relatively insensitive to endocrine therapy compared 
with luminal-A breast cancer, and to chemotherapy 
compared with HER2-enriched and basal-like breast 
cancers. Five studies examined the pathological complete 
response (pCR) rate following preoperative chemo-
therapy according to molecular subtype. Table 3 com-
pares the pCR for each molecular subtype in each study 
and demonstrates that the pCR rate is consistently lower 
in luminal-B breast cancer when compared with HER2 
and basal-like subtypes [25-29]. Th  ere were important 
methodological diﬀ  erences in these studies, including the 
method of subtype deﬁ  nition of the luminal-B subgroup 
(particularly the inclusion of ER-positive and HER2-
positive breast cancer in some studies), and diﬀ  erences in 
chemotherapy received.
Although luminal-B tumors are characterized by high 
proliferation, the likelihood of achieving pCR with pre-
operative chemotherapy is exceedingly low. In other 
high-risk breast cancer subtypes, pCR is a robust surro-
gate endpoint for disease-free survival and overall survival 
[30,31]. It is not clear whether pCR is a meaningful 
surrogate endpoint in luminal tumors. Paradoxically, 
large, low proliferative ER-positive tumors categorized 
with a low recurrence score by the OncotypeDx™ assay 
that fail to achieve pCR with preoperative chemotherapy 
experience excellent long-term survival [32]. In this 
study, there was no diﬀ  erence in long-term outcome for 
low recurrence score tumors that achieved pCR with 
preoperative chemotherapy compared with tumors in 
which there is residual invasive disease, although there 
were few low recurrence score tumors in this study that 
achieved pCR.
Response to endocrine therapy in the preoperative 
setting has also been explored as a surrogate marker for 
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residual proliferation after 10 to 14 days of preoperative 
endocrine therapy is prognostic for long-term RFS [33]. 
A correlative substudy of the IMPACT trial analyzed 158 
patients with paired biopsies (baseline and 2 weeks after 
endocrine therapy), and found that the absolute value of 
residual proliferation after short-term endocrine therapy, 
as assessed by the percentage of Ki-67 immunostaining, 
was strongly predictive of RFS; Ki-67 index <2.7% was 
asso  ciated with favorable RFS. Interestingly, the Ki-67 
index measured after 10 to 14 days of endocrine therapy 
was more predictive of long-term RFS than the pre  treat-
ment Ki-67 index [34]. pCR after preoperative endocrine 
therapy is rare [33,35-37]. Whether clinical or radio-
graphic response to preoperative endocrine therapy is 
predictive of long-term outcome in ER-positive disease is 
not ﬁ  rmly established.
Despite the problems with subtype classiﬁ  cation, the 
luminal-B subtype remains a clinically important classi  ﬁ  -
cation of breast cancer with prognostic and potential 
predictive implications. Weigelt and colleagues suggest 
that standardized methods and deﬁ  nitions for identi  ﬁ  -
cation of breast cancer molecular subtypes are necessary 
to incorporate molecular subtype classiﬁ  cation  into 
routine clinical practice [16]. HER2 and basal-like sub-
types can already be identiﬁ  ed using ﬂ  uorescence in situ 
hybridization and immunostaining for ER, PR and HER2. 
With regard to diﬀ   erentiating between luminal-A and 
luminal-B subtypes, various authors have tried to deﬁ  ne 
more pragmatic criteria that can broadly be applied to 
clinical practice. Some studies have used the level of ER 
expression to diﬀ   erentiate luminal-B from luminal-A 
subtypes [27], but this does not take into account the 
level of proliferation.
Table 2. Risk of early versus late relapse in molecular subtypes of breast cancer
      Early (<5 years) distant      Late (≥5 years) distant
     metastases  (n = 831)      metastases (n = 652)
   HR  95%  CI  P value HR  95%  CI  P value
Age          
  (<50 years vs. ≥50 years)  0.77  (0.56, 1.06)  NS  1.65  (0.97, 2.81)  NS
Tumor size            
  (≤2 cm vs. >2 cm)  1.31  (0.91, 1.86)  NS  1.18  (0.69, 2.01)  NS
Histological  grade        
  (2 vs. 1)  5.02  (1.80, 14.0)  <0.01  0.92  (0.48, 1.76)  NS
  (3 vs. 1)  7.22  (2.59, 20.2)  <0.01  0.70  (0.31, 1.60)  NS
Molecular  subtype        
  Luminal-A  1 – –  1 – –
  Luminal-B  2.86 (1.70,  4.80) <0.01  0.65 (0.24,  1.72)  NS
  HER2-positive  2.62 (1.50,  4.60) <0.01  1.41 (0.64,  3.12)  NS
  Basal-like  2.83 (1.92,  4.82) <0.01  0.96 (0.54,  1.70)  NS
Data from fi  ve publicly available datasets from patients with node-negative tumors who did not receive adjuvant systemic therapy. Molecular subtype assignment 
according to the subtype clustering method [17]. CI, confi  dence interval; HR, hazard ratio; NS, nonsignifi  cant.
Table 3. Pathological complete response rates post neoadjuvant chemotherapy in molecular subtypes of breast cancer
  Pathological complete response rate (%)
    Method of molecular    Luminal  Luminal  HER2-  Basal-
Author  n  classifi  cation  Defi  ning luminal B  A  B  positive  like
Esserman and   144  Microarray  Intrinsic gene set and hierarchical  –5  13  55  34
colleagues [25]      clustering (included some HER2+)
De Ronde and   191  Microarray  Intrinsic gene set and hierarchical  7  7  44  44
colleagues [26]       clustering (included some HER2+)
Bhargava and   359  IHC surrogate markers  ER–, HER2– 2  1  33  30
colleagues [27]
Carey and   107  IHC surrogate markers  ER+, HER2+ 0  15  36  27
colleagues [28]
Rouzier and   82  Microarray  Intrinsic gene set and hierarchical  7a 7 a 45  45
colleagues [29]       clustering (included some HER2+)
ER, estrogen receptor; IHC, immunohistochemistry. aIn Rouzier and colleagues [29], luminal-A and luminal-B subtypes were grouped together as the luminal subtype.
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potential unidimensional proliferation marker that could 
successfully diﬀ  erentiate luminal-B tumors from luminal-
A tumors in a clinically practical way [12]. Subtypes were 
assigned for a cohort of 357 breast cancers using micro-
array-based gene expression proﬁ   ling, and the Ki-67 
status, hormone receptor status and HER2 status were 
concurrently determined by immunohistochemistry. Th  e 
authors used receiver operating characteristic curves to 
determine the Ki-67 cut-oﬀ    point that distinguished 
luminal-A from luminal-B tumors, then applied it to an 
independent microarray series of 4,046 breast cancers. 
Th   ey were able to successfully demonstrate using 
immuno  histochemistry that determining the Ki-67 index 
can distinguish between the two subtypes [12]. However, 
arbitrarily applying a clinically relevant cut-oﬀ   point to a 
continuous variable such as Ki-67 that is unimodally 
distributed is problem  atic. Ki-67 immunohistochemistry 
is also limited by low reproducibility between labora-
tories, ongoing debate over both the optimal antibody for 
testing and the method for cell counting (manual versus 
automated), in addition to potential problems resulting 
from tumor heterogeneity [38]. Multigene prognostic 
assays, such as OncotypeDx™, are currently used to assess 
proliferation in providing independent prognostic 
information in early breast cancer [39]. Given their level 
of reproducibility and less potential for inﬂ  uence  by 
tumor heterogeneity, these assays may have potential 
advantages over a uni  dimensional marker such as Ki-67 
in assigning subtype classiﬁ  cation.
Potential targets in luminal-B breast cancer
Insulin-like growth factor signaling
In cancer, ligand activation of the insulin-like growth 
factor 1 receptor (IGF-1R) and its downstream pathways 
(phosphoinositide 3-kinase (PI3K)/AKT/mammalian 
target of rapamycin (mTOR) and Ras/Raf/MEK/ERK) 
stimulates tumor proliferation, survival, transformation, 
meta  stasis and angiogenesis [40]. Laboratory and epi-
demio  logical studies have demonstrated a link between 
cancer and insulin-like growth factor 1 (IGF-1) signaling 
[41]. IGF-1R is expressed in the majority of breast cancer 
(90 to 95%) and is often co-expressed with ER [42]. 
Cross-talk between ER and IGF-1R plays a critical role in 
tamoxifen resistance. Increased circulating plasma levels 
of IGF-1, a ligand for IGF-1R, identify women at increased 
risk of relapse on adjuvant tamoxifen [41]. Activation of 
IGF-1R signaling is associated with loss of PR expression, 
which itself is associated with high proliferative luminal-
B breast cancer, and with resistance to tamoxifen-
induced apoptosis [43]. Creighton and colleagues derived 
a signature of more than 800 genes whose expression was 
signiﬁ  cantly altered after exogenous IGF-1 stimulation in 
ER-positive MCF7 cells [44]. Activation of this IGF-1 
signature was seen in approximately 25% of ER-positive 
breast cancers and was associated with an increased risk 
of recurrence. Similar ﬁ  ndings were reported by Ignatiadis 
and colleagues with their 142-gene in silico signature of 
IGF-1 activation that was more commonly found in 
luminal-B tumors compared with luminal-A tumors [45].
Inhibition of IGF-1R signaling demonstrates synergistic 
activity in combination with endocrine therapy in 
preclinical models of ER-positive breast cancer [43,46]. 
Various approaches to interrupting the IGF-1 signaling 
axis have been developed. Although potential targets 
include growth hormone and growth-hormone-releasing 
hormone, the most advanced therapeutic approach has 
been the development of antibodies against IGF-1R that 
block IGF-1 ligand-mediated activation and small-
molecule inhibitors of the IGF-1R tyrosine kinase domain 
[47]. Table 4 outlines IGF-1R-targeted therapies that are 
being investigated in ER-positive breast cancer and other 
solid tumors. Th  e ﬁ  rst preliminary report of a random-
ized phase II trial of exemestane or fulvestrant and 
AMG-479, a fully human monoclonal antibody against 
IGF-1R, or matching placebo was presented at the 2010 
San Antonio Breast Cancer Symposium [48]. Th  is  study 
involved 156 patients with ER-positive metastatic breast 
cancer who had progressed following ﬁ  rst-line endocrine 
therapy for advanced disease or who had relapsed within 
12 months of completing adjuvant endocrine therapy. 
Th  is study failed to meet its primary endpoint, as the 
addition of AMG-479 did not improve progression-free 
survival. Th   e median progression-free survival for 
AMG-479 + endocrine therapy was 3.9 months, versus 
5.7 months for placebo + endocrine therapy (hazard 
ratio = 1.17, P = 0.44). Correlative studies of this trial and 
other ongoing studies will be essential to determine 
whether there is a signal of activity for IGF-1R inhibition 
in patients with luminal-B-like features, such as increased 
proliferation measured by Ki-67 immunostaining.
Fibroblast growth factor signaling
Th  e ﬁ   broblast growth factor (FGF) signaling system 
includes 22 ligands and four receptors [49], and is a 
highly complex growth factor signaling pathway that is 
responsible for many functions, including cell prolifera-
tion, survival and migration, through diﬀ  ering  down-
stream molecules or pathways [49]. Multiple studies 
indicate that FGF may also be involved in angiogenesis. 
One study demonstrated that the ligand FGF2 stimulates 
migration and proliferation of endothelial cells, whilst 
another study demonstrated that, under anti-vascular 
endothelial growth factor therapy, tumor angiogenesis 
can switch from vascular endothelial growth factor 
receptor dependence to ﬁ  broblast growth factor receptor 
(FGFR) dependence via upregulating FGF2, possibly 
explaining resistance to vascular endothelial growth 
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proliferation, survival, migration or angiogenesis, the 
FGF pathway clearly has oncogenic roles in many 
cancers. Th   ese roles occur through various genetic aber-
ra  tions that include ampliﬁ  cations, activating mutations, 
chromosomal translocations, SNPs and aberrant splicing 
at the post-transcriptional level.
In breast cancer, changes to FGF signaling are con-
sidered important for oncogenesis, mainly through 
ampliﬁ  cation  of  FGFR1 and FGFR2. Following erbB2/
HER2, FGFR1 is amongst the most commonly ampliﬁ  ed 
genes in breast cancer, present in up to 10% of all breast 
cancers [52]. Various reports have shown that FGFR1 
ampliﬁ   cation is most commonly associated with ER 
expres  sion, the absence of HER2 overexpression and 
lobular histology [53,54]. Additionally, the FGFR2 gene is 
ampliﬁ  ed in approximately 1 to 2% of breast cancers [52]. 
Genome-wide association studies have also shown that 
inherited SNPs in the FGFR2 gene are associated with an 
increased risk of developing ER-positive breast cancer, 
probably through an increase in FGFR2 transcription 
[52]. Although activating mutations in FGFR3 and 
FGFR4 occur in many types of human tumors, they seem 
to be rare in breast cancer [49].
Recent data suggest that the luminal-B subtype is 
enriched for FGFR1 gene ampliﬁ  cation [52]. One study 
examined tumors from two independent series of breast 
cancer for FGFR1 ampliﬁ   cation, demonstrating that 
FGFR1-ampliﬁ   ed cancers are frequently PR-negative, 
have a high proliferative rate assessed by Ki-67 immuno-
staining and are present in 16 to 27% of luminal-B breast 
cancer [53]. Furthermore, the same study demonstrated 
that FGFR1-ampliﬁ  ed breast cancer cell lines have both 
enhanced ligand-dependent and ligand-independent 
signaling, and are dependent upon FGFR signaling for 
anchorage-independent growth [53]. Th  ese authors also 
demonstrated that FGFR1-ampliﬁ  ed cells were resistant 
to endocrine therapy, but this could be reversed by 
knockdown of FGFR1 [53]. Other studies have also 
observed that resistance to endo  crine therapy can be 
Table 4. Targeted treatment in luminal-B breast cancer
Pathway Agent  Supplier  Class  Phase  Study design  Eligible population
IGF BMS-754807 BristolMyersSquibb  IGF-1R/IR TKI II BMS-754807 ± letrozole  ER-positive locally advanced/metastatic 
breast cancer, progressed on prior 
nonsteroidal aromatase inhibitors
Cixutumumab ImClone IGF-1R mAb I/II Cixutumumab and 
temsirolimus
Locally advanced/metastatic breast cancer 
progressed on one or two chemotherapy 
lines
MK-0646 Merck IGF-1R mAb I/II MK-0646 and fulvestrant and 
dasatinib
Locally advanced/metastatic ER-positive 
breast cancer with no previous treatment in 
metastatic setting
Dalotuzumab Merck IGF-1R mAb II Dalotuzumab and 
ridaforolimus versus standard 
care
ER-positive locally advanced/metastatic 
breast cancer, progressed on at least one line 
of endocrine therapy
OSI-906 OSI IGF-1R/IR TKI II OSI-906 and endocrine 
therapy ± erlotinib
ER-positive metastatic breast cancer, treated 
with ≤4 chemotherapy regimens
CP-758171 Pfi  zer IGF-1R TKI I CP-758171 for two cycles 
prior to curative surgery
Operable early breast cancer
FGF TKI-258 Novartis FGFR/VEGFR TKI II TKI-259 single agent HER2-negative, FGFR1 amplifi  ed and FGFR1 
normal metastatic breast cancer
AZD-4547 Astra Zeneca FGFR TKI II Exemestane ± AZD-4547 ER-positive locally advanced/metastatic 
breast cancer with high levels of FGFR1 
expression
PI3K/AKT MK-2206 Merck AKT inhibitor II MK-2206 single agent Metastatic breast cancer with PIK3CA 
mutation and/or PTEN loss, progressed on at 
least one line of therapy
MK-2206 Merck AKT inhibitor II MK-2206 and endocrine 
therapy
ER-positive metastatic breast cancer 
progressed on endocrine therapy
XL-147 Exelixis PI3K inhibitor II XL-147 and letrozole ER-positive metastatic breast cancer 
refractory to nonsteroidal aromatase 
inhibitors
XL-765 Exelixis PI3K/mTOR 
inhibitor
II XL-765 and letrozole ER-positive metastatic breast cancer 
refractory to nonsteroidal aromatase 
inhibitors
ER, estrogen receptor; FGF, fi  broblast growth factor; FGFR, fi  broblast growth factor receptor; IGF, insulin-like growth factor; IGF-1R, insulin-like growth factor 1 
receptor; mAb, monoclonal antibody; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase; TKI, tyrosine kinase inhibitor; VEGFR, vascular 
endothelial growth factor.
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and the use of a small molecule FGFR tyrosine kinase 
inhibitor [55]. Th  ese ﬁ  ndings all suggest that the FGF 
pathway, and more speciﬁ  cally FGFR1 gene ampliﬁ  cation, 
may be a major contributor to the poor prognosis 
observed in luminal-B breast cancer, through increased 
proliferation and resistance to endo  crine therapy.
Preclinical models of breast cancer cells ampliﬁ  ed for 
FGFR1 or FGFR2 have demonstrated sensitivity to 
inhibition of FGFR [49]. Th   is has led to several proof-of-
concept early-phase clinical trials using FGFR inhibitors. 
Several antibodies and small-molecule inhibitors of 
FGFR are currently in clinical testing. First-generation 
tyrosine kinase inhibitors also inhibit VEGFR2 due to 
structural similarity between the two tyrosine kinase 
domains [52]. Table 4 lists some of the current agents 
targeting the FGF pathway in breast cancer clinical trials. 
An important challenge for all of these studies is the 
identiﬁ  cation of patients whose tumors harbor genetic 
ampliﬁ  cation  of  FGFR1 or FGFR2. Like erbB2/HER2, 
chromosome  in situ hybridization and ﬂ  uorescence in 
situ hybridization are the dominant methods used to 
identify gene ampliﬁ  ca  tion in paraﬃ   n-embedded tumor 
samples.
Phosphoinositide 3-kinase signaling
Deregulated PI3K signaling has been implicated in many 
aspects of carcinogenesis [56]. Genetic aberrations along 
the pathway can occur anywhere from the upstream 
growth factor receptors to downstream target molecules, 
regulatory molecules and PI3K itself [56]. Th  ese  genetic 
aberrations have the potential to change a number of cell 
functions that contribute to the transformed phenotype, 
including cell growth and proliferation, diﬀ  erentiation, 
cell survival, adhesion and cell motility [56]. Subse-
quently, the PI3K pathway – including its enzymes, 
targets and regulators – is considered an important 
potential therapeutic target in cancer.
In breast cancer, the PI3K pathway is frequently 
activated. Ampliﬁ  cation of upstream receptors such as 
erbB2/HER2, loss of negative regulators such as PTEN, 
ampliﬁ   cation of downstream targets such as Akt, and 
activating mutations or genetic ampliﬁ  cation of the α-
catalytic subunit of PI3K (PIK3CA) have all been des-
cribed in breast cancer. PIK3CA somatic mutations occur 
in approximately 25% of breast cancer [57,58]. In luminal-
B breast cancer, the role of PI3K signaling is being 
deﬁ  ned. Th  ere appear to be no diﬀ  erences in the fre-
quency of PIK3CA  mutation between luminal-A and 
luminal-B breast cancers [58]. A recent preclinical study 
has demon  strated that increased expression of PI3K 
pathway genes is a feature of luminal-B breast cancer 
[59]. Growth inhibition induced by endocrine therapy in 
luminal-B breast cancer cell lines could be signiﬁ  cantly 
increased by adding a selective PI3K inhibitor, suggesting 
that PI3K inhibitors may have a role in luminal-B breast 
cancer [59].
In breast cancer, the initial studies targeting the PI3K 
pathway involved rapamycin analogs or mTOR inhibitors. 
A phase II study of ER-positive breast cancer in the 
neoadjuvant setting compared 4 months of letrozole 
treatment with 4 months of letrozole and everolimus 
treat  ment, an oral mTOR inhibitor [36]. Although the rate 
of sonographic response was only marginally improved 
with the addition of everolimus to letrozole (68% vs. 59%, 
P  =  0.062), there was a much greater improvement in 
antiproliferative response, deﬁ   ned as day 15 Ki-67 
immuno  staining <2.7% (57% vs. 30%, P  <0.01). Th  e 
authors also noted that the rate of anti-proliferative 
response in the everolimus and letrozole arm was higher 
in tumors with PIK3CA mutations [36].
Recently, a negative intracellular signaling feedback 
loop between the mTOR complex 1 and the IGF-1 
signaling axis has been discovered [60]. Intracellular 
levels of IRS1, a key mediator of IGF-1R signaling, are 
increased when mTOR complex 1 is inhibited by 
everolimus and other similar mTOR inhibitors, leading to 
paradoxical activation of Akt [61]. Preclinical models 
suggest robust activity for dual IGF-1R and mTOR 
inhibition [62,63]. A recent phase I study demonstrated 
that this combined therapy may be eﬀ   ective in breast 
cancer, where ﬁ  ve out of 23 breast cancer patients had 
either partial response, prolonged stable disease or partial 
metabolic response [64]. Th   e combination appeared 
particularly active in luminal-B like breast cancer – deﬁ  ned 
as ER-positive with Ki-67 immuno  staining ≥15% – as three 
out of 10 patients in this trial, all of whom were heavily 
pretreated, achieved a partial response by the Response 
Evaluation Criteria in Solid Tumors.
Th  ere is great enthusiasm for highly speciﬁ  c  PI3K 
inhibitors that are currently in early development. Th  ey 
range from pure pan-PI3K inhibitors to isoform-speciﬁ  c 
PI3K inhibitors, to dual inhibitors of both PI3K and 
mTOR, to Akt inhibitors. Currently, most early-phase 
studies using these agents attempt to select patients with 
genetic aberrations in this pathway. A recent preclinical 
study, however, suggested that PIK3CA mutation, but not 
PTEN loss, confers sensitivity to mTOR inhibitors [65]. 
In the clinical setting, one study retrospectively corre-
lated the PIK3CA mutation status of patients with 
response rates from PI3K/Akt/mTOR inhibition. Th  ese 
authors observed higher responses in the PIK3CA mutant 
population (35% partial responses) compared with the 
PIK3CA wild-type population (6% partial responses) [66]. 
Targeting the PI3K pathway appears very promising, 
although more extensive study is required – particularly 
in identifying patients who will beneﬁ   t. Novel agents 
targeting this pathway are listed in Table 4.
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Cyclin D1 is ampliﬁ  ed in approximately 10% of breast 
cancer and is known to have a role in driving proliferation 
through its interaction with cyclin-dependent kinases 
such as CDK4 [67]; subsequently, it has been suggested 
that cyclin-directed therapies may have a role in luminal-
B subtypes, where proliferation is an important factor 
[67]. Cyclin inhibitors are currently in early-phase 
development.
Recent preclinical research has identiﬁ  ed a potential 
breast cancer oncogene, ZNF703, implicated in the 
luminal-B subtype [68]. In this study ZNF703  was 
signiﬁ  cantly ampliﬁ  ed in luminal-B tumors, and its over-
expression was associated with poor clinical outcome 
[68]. In cell lines, overexpression of ZNF703 induced cell 
proliferation independent of estradiol stimulation [68]. 
Th  e investigators also observed that ZNF703 is ER 
regulated and may have a role in cancer stem cell self-
renewal [68], suggesting a potential role for ZNF703 
inhibition in luminal-B breast cancer.
Another recent study has indicated an association 
between luminal-B tumors and overexpression of the 
scaﬀ  old protein NHERF1 (sodium–hydrogen exchanger 
regulatory factor 1). NHERF1 expression is associated 
with poorer survival and resistance to endocrine therapy 
in ER-positive breast cancer [69]. Further study is 
required to determine whether NHERF1 is an appropriate 
candidate for targeted therapy.
Conclusion
Gene expression studies have led to the identiﬁ  cation of 
luminal-B breast cancer, a subtype of ER-positive breast 
cancer deﬁ  ned by increased proliferation, relative resis-
tance to chemotherapy compared with other highly 
proliferative breast cancers, and poor outcome with 
endocrine therapy. Assigning the luminal-B subtype to 
individual breast cancers has been problematic, however, 
as the robustness of single subtype classiﬁ   ers is sub-
optimal. Rather than approaching luminal-B cancer as a 
ﬁ   xed biological entity, it is more clinically useful to 
consider the luminal-B phenotype as a conceptual frame-
work, recognizing that proliferation in ER-positive/
HER2-negative tumors exists along a continuum. 
Identiﬁ  cation of highly proliferative ER-positive/HER2-
negative tumors – whether through histological grading, 
the Ki-67 labeling index, or a multigene signature – is 
useful to separate aggressive luminal-B-like tumors with 
a risk of early relapse from more indolent luminal-A-like 
tumors that are adequately treated with endocrine 
therapy alone. In an eﬀ  ort to improve survival in luminal-
B breast cancer, there has been a recent focus on 
particular molecular pathways where development of 
eﬃ     cacious therapeutic agents may alter the natural 
history of the disease. For these novel treatments to have 
their desired eﬀ  ect, however, additional work is needed 
to characterize the drivers of aggressive biology, and 
future trials should acknowledge the molecular hetero-
geneity of ER-positive breast cancer and separate the 
more indolent luminal-A breast cancers from their more 
proliferative luminal-B-like counterparts.
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